Question · asked by 1 review
Deferasirox vs deferoxamine: All‐cause mortality
- Population
- patients with managing transfusional iron overload in people with sickle cell disease
- Intervention
- Deferasirox
- Comparison
- deferoxamine
- Outcome
- All‐cause mortality
It is very uncertain whether deferasirox changes mortality compared with deferoxamine (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Deferasirox vs deferoxamine Mortality · patients with sickle cell disease and transfusional iron overload It is very uncertain whether deferasirox changes mortality compared with deferoxamine (very low certainty). Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane Headline outcomes only | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Deferasirox for managing transfusional iron overload in people with sickle cell disease 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Deferasirox vs deferiprone (DFO) · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.